EGFR inhibitors: what have we learned from the treatment of lung cancer?

@article{Giaccone2005EGFRIW,
  title={EGFR inhibitors: what have we learned from the treatment of lung cancer?},
  author={Giuseppe Giaccone and Jos{\'e} Antonio Rodr{\'i}guez},
  journal={Nature Clinical Practice Oncology},
  year={2005},
  volume={2},
  pages={554-561}
}
The identification of somatic mutations in the epidermal growth factor receptor (EGFR) gene and promising clinical trial data showing a favorable clinical response to associated gefitinib and erlotinib in non-small-cell lung cancer patients was a major breakthrough in the field. Should patient selection for treatment with these drugs, however, be solely based on mutational EGFR status? Giaccone and Rodriguez discuss ways in which mutational analysis could be optimized, highlight factors that… CONTINUE READING

Tables and Topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.
SHOWING 1-10 OF 45 CITATIONS

The distinctive nature of adenocarcinoma of the lung

  • OncoTargets and therapy
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 54 REFERENCES

A phase II trial of cetuximab as therapy for recurrent non - small cell lung cancer [ abstract ]

Z Tsuchihashi
  • J Clin Oncol
  • 2005

Angiogenesis and lung cancer: prognostic and therapeutic implications.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

H Shigematsu
  • J Natl Cancer Inst
  • 2005